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Strong BCL10 nuclear expression identifies gastric MALT lymphomas that do not respond to H pylori eradication
Approximately 75% of gastric mucosa associated lymphoid tissue (MALT) lymphomas can be cured by Helicobacter pylori eradication. 1 It would be very useful to identify, at the time of diagnosis, the 25% of cases of gastric MALT lymphoma that will not respond to H pylori eradication. In general, lymphomas at stage II E or above do not respond to H pylori eradication. [2] [3] [4] However, the prognostic value of staging in stage I E cases is very limited, although tumours that involve the muscularis propria or serosa (stage I E2 ) show a higher failure rate than those restricted to the mucosa and submucosa (stage I E1 ). [2] [3] [4] Paradoxically, the majority of gastric MALT lymphomas at diagnosis are at stage I E but 20% of these cases will not respond to H pylori eradication.
In a previous study, we have examined the value of t(11;18)(q21;q21) in prediction of the response of gastric MALT lymphoma to H pylori eradication. Among the 111 cases of gastric MALT lymphoma studied, t(11;18)(q21;q21) was present in 42/63 (67%) non-responsive cases, including 26/43 (60%) at stage I E . 5 In contrast, translocation was detected in only 2/ 48 responsive cases and the two translocation positive cases showed a temporary response to H pylori eradication. 5 Based on the same series of cases, we examined the value of t(1;14)(p22;q32)/IGH-BCL10 in prediction of the response of gastric MALT lymphomas to H pylori eradication.
Of the 111 cases examined, 75 including 35 from the complete regression group and 40 from the non-responsive group, had adequate tissue specimens for evaluation of BCL10 staining. Two cases showed strong BCL10 nuclear staining in virtually all tumour cells (fig 1) , similar to that seen in t(1;14)(p22;q32) positive cells, 6 while the remaining cases displayed either weak cytoplasmic or weak nuclear staining. Both cases with strong BCL10 nuclear staining were from the H pylori eradication non-responsive group; one case (case No 1) had stage II E disease and showed no response 12 months after H pylori eradication while the other (case No 2) had stage I E disease and showed no response eight months after H pylori eradication. As shown in our previous study, both cases were t(11;18)(q21;q21) negative. 5 To ascertain whether the two cases that showed strong BCL10 nuclear staining were positive for t(1;14)(p22;q32) or variant, interphase fluorescence in situ hybridisation (FISH) with BCL10 break-apart dual colour probes, IGH break-apart probes, IGk break-apart probes, and BCL10/IGH dual colour dual fusion translocation probes were performed. 6 7 Both cases failed to show evidence of BCL10 gene break or amplification. Case No 2 showed an IGH break, but FISH with BCL10/IGH dual colour dual fusion translocation probes failed to show evidence of BCL10/IGH translocation. To further investigate these cases, we performed real time quantitative reverse transcription-polymerase chain reaction of BCL10 mRNA. Unfortunately, adequate tissue materials were available only in case No 2. The level (DCt = 3.4) of BCL10 mRNA expression in this case was compatible with that in MALT lymphoma with t(1;14)(p22;q32) (mean 1.60 (SD 2.37)), well above that in those without the translocation (6.94 (1.72)). 6 To further assess the impact of t(1;14)(p22;q32) on the clinical behaviour of MALT lymphoma, we retrospectively reviewed the clinical presentation of 11 cases, including six from the stomach with known BCL10 involved translocation (table 1) . Of these cases, nine including all those from the stomach, were at stage II E or above. Although clinical presentation and follow up data were not available in each case, three cases (Nos 1, 2 and 7) presented unusual wide dissemination, Table 1 Crohn's disease activity index (CDAI) in CD subjects inoculated with infective larvae (L3i). Subsequently, the five CD subjects first inoculated were reinoculated from week 27 to week 30 and four CD subjects with chronic and mostly active disease were inoculated with larvae sourced from one of the authors L3i, n 3rd stage N americanus larvae inoculated percutaneously; P, prednisone n mg/day; A, azathioprine n mg/day; M, methotrexate n mg/week.
including pleural effusion, and blood and bone marrow involvement (table 1) . Taken together, our results suggest that gastric MALT lymphomas with strong BCL10 nuclear expression or t(1;14)(p22;q32) are mostly likely resistant to H pylori eradication. Interferon-b plus ribavirin for patients with hepatitis C virus genotype 1: a randomised pilot trial
The rate of sustained eradication of hepatitis C virus (HCV) in response to a combination of interferon-a and ribavirin remains unsatisfactory in patients with genotype 1 infection. 1 No effective alternative treatment is currently available for non-responders. Interferon-b is also a type I interferon commonly used to treat chronic HCV infection in Japan. A previous study showed that a 24 week course of therapy with interferon-b plus ribavirin resulted in sustained loss of HCV in three of nine patients with chronic hepatitis C. 2 However, the efficacy and safety of interferon-b combined with ribavirin has yet to be fully evaluated. We report the results of a randomised pilot trial comparing interferon-b plus ribavirin with interferon-a plus ribavirin in patients with HCV genotype 1 who poorly responded to interferon-a plus ribavirin. A total of 28 patients with HCV genotype 1 were given 6 MU of recombinant interferon-a2b (Schering-Plough, Kenilworth, New Jersey, USA) by intramuscular injection daily for four weeks. Twenty seven patients (16 men and 11 women; mean age 47 (¡8) years) in whom HCV RNA was detected in serum on polymerase chain reaction at week 2 were included in this study and randomly assigned to receive one of two regimens from week 5. Fifteen patients continued to receive 6 MU interferon-a2b intramuscularly, given daily from week 5 to week 8, and three times weekly from week 9 to week 24 (interferon-a group). The other 12 patients were assigned to 6 MU natural interferon-b (Toray Industries Inc., Tokyo, Japan), given by intravenous injection daily from week 5 to week 8, and three times weekly from week 9 to week 24 (interferon-b group). Ribavirin (Schering-Plough) was concurrently administered at a daily dose of 600 mg to patients who weighed 60 kg or less and 800 mg to those who weighed more than 60 kg. At the time of this study, a 24 week course of interferon-a plus ribavirin was commonly used in Japan. The data were analysed according to intention to treat.
Baseline characteristics of the patients in the treatment groups were similar. At week 4 of therapy, when treatment was randomly assigned, the proportion of patients without detectable HCV RNA in serum did not differ between the interferon-a group and interferon-b groups (table 1). The proportion of patients without HCV RNA in serum was higher in the interferon-b group than in the interferon-a group at week 12, but did not differ between the groups at the end of treatment (week 24). However, 24 weeks later (week 48), the proportion of patients with a sustained virological response was significantly higher in the interferon-b group than in the interferon-a group. During treatment, neutralising antibodies to interferon were detected in two patients in the interferon-a group and in no patients in the interferon-b group. Leucocyte, neutrophil, and platelet counts and haemoglobin concentrations were similar in two groups. Therapy was discontinued because of serious adverse events (including depression) in three patients in the interferon-a group; all 12 patients in the interferon-b group completed 24 weeks of treatment. The dose of ribavirin was reduced because of anaemia in eight patients in the interferon-a group and in four in the interferon-b group.
We enrolled patients who did not have a favourable early response to treatment with interferon-a and ribavirin. Antibodies to interferon, which sometimes develop in Conflict of interest: None declared. 
